We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 42.00 | 0.37% | 11,292.00 | 11,292.00 | 11,294.00 | 11,362.00 | 11,232.00 | 11,250.00 | 382,838 | 11:47:14 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.38 | 174.99B |
From Apr 2019 to Apr 2024
By Sabela Ojea
AstraZeneca PLC (AZN.LN) said Friday that a supplemental biologics license application and granted priority review for the Imfinzi drug, which fights against untreated extensive-stage small-cell lung cancer, has been accepted by the U.S. Food and Drug Administration.
The drug maker said a prescription-drug user fee act date--the deadline for the FDA to review the application--is set for the first quarter of 2020.
Small-cell lung cancer is an aggressive, fast-growing form of lung cancer that recurs and progresses rapidly, the London-listed company said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 29, 2019 02:28 ET (07:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
